Status:
UNKNOWN
Magnesium Replacement and Hyperglycemia After Kidney Transplantation
Lead Sponsor:
Oslo University Hospital
Conditions:
Hypomagnesemia
Kidney Transplantation
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The insulin receptor is dependent on magnesium and hypomagnesemia is associated with increased insulin resistance and decreased insulin secretion and action. Recent data suggest that hypomagnesemia ma...
Eligibility Criteria
Inclusion
- Kidney transplant recipients more than one year after transplantation
- Hypomagnesemia (\< 0.7 mmol/L)
- Age ≥ 18 years and able to give written informed consent
Exclusion
- Current treatment with magnesium containing medication or supplements
- Current medical treatment for diabetes
- Conditions impairing magnesium absorption from the gastrointestinal tract (e.g. short bowel syndrome, chronic pancreatitis)
- Subjects with primary non-graft function and subjects with need of dialysis therapy \>2 months or graftectomy at any time point after transplantation
Key Trial Info
Start Date :
February 25 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2022
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04382157
Start Date
February 25 2020
End Date
August 31 2022
Last Update
September 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oslo University Hospital
Oslo, Norway